What is Leerink Partnrs’ Estimate for NAMS Q1 Earnings?

NewAmsterdam Pharma (NASDAQ:NAMS) – Investment analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of NewAmsterdam Pharma in a report released on Tuesday, December 17th. Leerink Partnrs analyst R. Ruiz forecasts that the company will post earnings of ($0.20) per share for the quarter. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for NewAmsterdam Pharma’s Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.25) EPS, FY2026 earnings at ($1.15) EPS and FY2027 earnings at ($1.20) EPS.

A number of other equities research analysts have also weighed in on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $31.00 target price on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Scotiabank raised their target price on NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a report on Wednesday, December 11th. Piper Sandler reaffirmed an “overweight” rating and set a $37.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Finally, Needham & Company LLC reissued a “buy” rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $36.20.

NewAmsterdam Pharma Stock Down 1.7 %

NewAmsterdam Pharma stock opened at $25.46 on Friday. The firm’s fifty day moving average price is $21.16 and its two-hundred day moving average price is $18.90. NewAmsterdam Pharma has a 1-year low of $10.29 and a 1-year high of $27.29.

Insider Activity

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 45,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total value of $707,400.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Nap B.V. Forgrowth sold 166,011 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $25.39, for a total transaction of $4,215,019.29. Following the completion of the transaction, the insider now owns 11,150,461 shares in the company, valued at approximately $283,110,204.79. The trade was a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 252,814 shares of company stock valued at $5,970,327 over the last three months. Corporate insiders own 19.50% of the company’s stock.

Institutional Investors Weigh In On NewAmsterdam Pharma

Hedge funds have recently modified their holdings of the stock. Banque Cantonale Vaudoise purchased a new stake in NewAmsterdam Pharma in the second quarter worth $38,000. Quarry LP grew its stake in shares of NewAmsterdam Pharma by 2,469.2% during the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock worth $108,000 after acquiring an additional 6,247 shares during the period. Barclays PLC increased its holdings in NewAmsterdam Pharma by 1,813.4% in the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after acquiring an additional 7,199 shares during the last quarter. Bellevue Group AG bought a new stake in NewAmsterdam Pharma in the 3rd quarter valued at about $128,000. Finally, XTX Topco Ltd purchased a new stake in NewAmsterdam Pharma during the third quarter valued at about $187,000. Institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.